W.H.P.M., Inc. Files Patent Infringement Lawsuit Against Healgen Scientific LLC

Share Article

The lawsuit seeks compensatory damages in addition to a permanent injunction on Healgen’s manufacture, sale or import of products alleged to be infringing on W.H.P.M.’s patent.

Our intellectual property and our investments in R&D must be protected. As a result of activities we allege infringe on W.H.P.M.’s patent, we are taking legal action.

W.H.P.M., Inc. (“W.H.P.M.”), a leading developer and manufacturer of rapid drugs of abuse and medical diagnostic devices, announced today that it has filed a lawsuit for patent infringement against Healgen Scientific Limited Liability Company, a Texas company (“Healgen”).

The lawsuit, filed in the United States District Court for the Southern District of Texas, Houston Division (Case number: 4:2018cv02302) alleges infringement of United States Patent No. 7,927,562 (“'562 Patent”), titled “Collection and Assay Device for Biological Fluid.”

W.H.P.M. alleges that Healgen has been and is now infringing the '562 Patent by making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test (“Accused Healgen Products”). WHPM further alleges that Healgen knowingly and intentionally causes its customers to directly infringe the '562 Patent through various means, including but not limited to, the marketing, selling and offering for sale the Accused Healgen Products to its customers.

WHPM seeks monetary damages and injunctive relief enjoining Healgen and any others in any way associated with them from making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test or in any other manner infringing, inducing others to infringe or contributing to the infringement of the '562 Patent.

“We have invested significant time and resources into developing our oral fluid drug tests and collection systems,” says Dr. John Wan, founder and President of W.H.P.M., Inc. “Our intellectual property and our investments in R&D must be protected. As a result of activities we allege infringe on W.H.P.M.’s patent, we are taking legal action.”

W.H.P.M intends to vigorously defend its intellectual property and is prepared to pursue additional action against those infringing on its intellectual property.

About W.H.P.M., Inc.
W.H.P.M., Inc., established in 1993, is headquartered in Irwindale, Calif. W.H.P.M. is a global leader in the research, development, and deployment of the most advanced and innovative one-step membrane tests and medical diagnostics devices on the market today. W.H.P.M. offers customers a variety of fast-turnaround services for rapid diagnostics, including OEM production, customized assembly, and private labeling. It assists companies in rapidly producing a wide array of products by utilizing its extensive experience in advanced bio-technology and design/manufacturing systems. Learn more at whpm.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aaron Wangen
Visit website

Media

W.H.P.M. logo image